Creative BioTherapeutics LLC, a biotechnology company developing investigational approaches to address cancer recurrence and treatment resistance, has been named a 2026 Prix Galien USA nominee in the Best Startup category. The recognition centers on the company's lead investigational biologic candidate, CBT300, and arrives at a critical stage in its development as it prepares for commercial-scale production and an Investigational New Drug (IND) filing.
The Prix Galien USA Awards recognize scientific innovation intended to improve human health. For Creative BioTherapeutics LLC, the nomination provides external validation at a pivotal moment and draws attention to a scientific challenge that has driven the company from its inception: what happens when cancer survives treatment. Recurrence and treatment resistance remain formidable obstacles across numerous forms of cancer, and the company believes understanding the mechanisms that allow malignant cells to persist, adapt and evade therapeutic and immune pressure is essential to developing new approaches.
CBT300 is an investigational biologic being developed as a multi-cancer, platform candidate intended to be evaluated for its potential to interfere with drug-resistance pathways, immune-evasion mechanisms and cellular processes associated with recurrence and metastasis. The candidate remains in preclinical development and has not been approved by the U.S. Food and Drug Administration for the treatment of cancer or any other disease. According to the company, preclinical safety and efficacy studies have been completed, and it is now preparing for commercial-scale drug production and an IND filing as it works toward first-in-human clinical evaluation.
Creative BioTherapeutics also recently received FDA feedback regarding its proposed safety program for CBT300. According to the company, the agency agreed with its proposed approach for satisfying the remaining safety requirements needed to progress toward an IND filing. The plan uses alternative methods of safety validation in place of certain animal toxicity studies, an approach the company says will avoid approximately $1.2 million in animal-study costs while allowing it to complete the proposed safety program. This regulatory alignment could accelerate the timeline toward clinical testing and reduce development expenses, which is significant for a startup operating in the capital-intensive field of oncology drug development.
The nomination carries particular weight for CEO and Founder Dr. Anita Davidson, who witnessed the toll of cancer recurrence during years as a clinician, including the loss of a 16-year-old patient whose cancer returned after treatment. "Being recognized by the Galien Foundation is deeply meaningful to us because this work has always been about the patients behind the science," said Davidson. "We have seen what recurrence and treatment resistance can do to individuals and families. CBT300 grew from a belief that we have to keep asking harder questions about why cancer returns and why treatments that initially work can eventually stop working."
Creative BioTherapeutics was founded by Anita Davidson and her husband, biochemist and Chief Scientific Officer Dr. Don Davidson, whose different experiences with cancer converged around a common question: could they help develop a different approach to one of oncology's most persistent challenges? Don brought decades of scientific experience in drug discovery and development. Together, those experiences led to the formation of the company and eventually to CBT300.
"The recognition is exciting, but it doesn't change the scientific standard we have to meet," said Dr. Don Davidson. "Our responsibility remains to follow the data, challenge our assumptions and understand the biology as completely as possible. Every step has to earn the next step."
The 20th annual Prix Galien USA Awards Ceremony is scheduled for October 29, 2026, at the American Museum of Natural History in New York City. As that date approaches, Creative BioTherapeutics will continue its work on CBT300 while engaging with the broader scientific, biotechnology and oncology communities around the challenges of recurrence and treatment resistance. The nomination amplifies the company's platform and could attract further investment and partnerships, but it also reinforces the responsibility to deliver rigorous science.
"We are grateful for the nomination, but we also understand what it asks of us," Davidson added. "Recognition brings visibility, and visibility brings responsibility. Our job now is to keep doing the work, keep following the science and keep remembering the patients and families who are waiting for better answers."
